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Abstract
Background: Understanding the predictors of appropriate implantable cardioverter defibrillator 
(ICD)   therapy   could   help   to   better   identify   candidates   for   ICD   implantation.
Methods:  One hundred and sixty two patients with ICD (111 with coronary artery disease 
[CAD] and 51 with dilated cardiomyopathy [DCM]) were included in the study. Clinical, 
electrocardiographic,   and   ICD   stored   data   and   electrograms   were   collected.  
Results: During mean follow up of 15±11 months 54 patients (33%) received ≥ 1 appropriate 
ICD therapy (AICDT). We used binary logistic regression analysis with forward selection 
method to find the potential predictors of appropriate ICD therapy after device implantation. 
Male gender (odds ratio [OR] = 2.76, 95% confidence interval [CI] = 1.1 – 7.1, P=0.021), DCM 
as underlying heart disease (OR = 4.2, 95% CI = 1.9 – 9.5, P=0.001), and QRS width > 100 ms 
(OR = 2.58, 95% CI = 1.2 – 5.4, P=0.010) were correlated with increased likelihood of AICDT 
during the follow up period. In subgroup analysis of the patients with CAD and DCM, QRS 
duration > 100 ms was correlated with the probability of ≥ 1 AICDT. In our patients indication 
of ICD implantation (primary versus secondary prevention) did not influence probability of ≥ 1 
AICDT (adjusted OR = 1.66, 95% CI = 0.7 – 4.0, Mantel-Haenszel P value P=0.355.)  
Conclusion:  QRS width could be used as an additional simple risk stratifier beyond EF to 
identify potential candidates who would benefit more from ICD implantation. This may have 
practical implications for patient selection especially in developing countries. Indication of ICD 
implantation (primary versus secondary prevention) did not affect the probability of ≥ 1 AICDT 
during   the   follow   up   period.                                                                  
            
Keywords:  Implantable cardioverter-defibrillator, Appropriate ICD therapy, Coronary artery 
disease, Dilated cardiomyopathy   
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Introduction
              
               Development of implantable cardioverter-defibrillators (ICD) has been a dramatic 
advancement in the management of patients with  ventricular arrhythmias. A major issue in 
patients with ICD is the high incidence of ICD therapies1-7, which have a major effect on 
morbidity and quality of life.4,5 Knowing the predictors of appropriate ICD therapy could also 
help to better identify candidates for ICD therapy. This is a retrospective single centre study to 
identify potential predictors of appropriate ICD therapies.                                           
Methods
Patients Population: Between January 2001 and January 2005, 162 patients with coronary artery 
disease (CAD) or dilated cardiomyopathy (DCM) underwent ICD implantation at our centre. 
Among these 94 (58%) received single-chamber and 68 (42%) received dual-chamber ICD. The 
left ventricular ejection fraction (EF) was measured by transthoracic echocardiography. All the 
patients gave written informed consent for the procedure of ICD implantation. The mean age 
was  58.2  ±  13.5  years.  Table  1  and  2  show   the  basic  characteristics  of   the  patients.
Implanted ICDs and programming: The implanted devices were manufactured by Medtronic 
([GEM-VR, GEM-DR, GEM-II-VR, GEM-II-DR, GEM-III-VR, GEM-III-DR, Marquis-VR, 
Marquis-DR] Medtronic Inc., Minneapolis, MN, USA) and St. Jude ([Photon-VR, Photon-DR, 
Photon-µ-VR, Photon-µ-DR, Atlas-VR, Atlas-DR, Epic-VR, and Epic-DR] St. Jude Medical 
Inc. Sylmar, CA, USA). In implanted devices all the detection and discrimination criteria were 
activated with the nominal values. In all the devices we defined ventricular fibrillation zone (300 
ms) plus one VT zone (400 ms). If the patient had an episode of spontaneous or induced 
sustained monomorphic VT slower than 370 ms we extended the VT zone to VT cycle length 
plus 40ms. In the VT detection zone the first therapy was three antitachycardia bursts pacing. 
We used the nominal values of the ICDs for the duration and tachyarrhythmia detection criteria.
ICD Data Storage and Retrieval:  After ICD implantation the patients were followed on a 
regular basis (3 months) and upon receiving high voltage therapy in our outpatient ICD clinic. 
The devices were interrogated at each session and the complete set of data (including 
intracardiac electrograms) was recorded on floppy diskettes. The summary of the episodes were 
also recorded in the patient’s file. The floppy diskettes were used in this study to retrieve all 
spontaneous sustained arrhythmia episodes resulted in ICD therapy. These episodes resulted in 
ICD therapies, studied by two independent electrophysiologists (AA and MRD) to define the 
diagnosis. In case of discrepancy in diagnosis the final analysis of the arrhythmia episode was 
made by a consensus of three electrophysiologists (AA, MRD, and MH). Beside from diagnosis, 
the   time   of   arrhythmia   after   implantation   and   the   mode   of   therapy   were   recorded.  
Definitions: Appropriate ICD therapy was defined as an antitachycardia pacing or shock therapy 
for ventricular tachycardia or fibrillation. Indication of ICD implantation was defined as 
secondary prevention (n=117) in patients who had experienced aborted sudden cardiac death, 
sustained ventricular arrhythmia, or syncope (whose electrophysiologic study [using three basic 
drive cycle lengths of 600, 500 and 400 with up to three premature extra-stimuli from right 
ventricular apex and/or outflow tract] who showed inducible sustained hemodynamically 
unstable ventricular arrhythmias). The indication of ICD implantation in all the other patients (33 
patients with CAD without history of syncope had left ventricular ejection fraction < 40%, 
nonsustained ventricular tachycardia on Holter monitoring, and inducible sustained Mohammad 
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hemodynamically unstable ventricular arrhythmia during electrophysiologic study; and 13 
asymptomatic patients with DCM with nonsustained ventricular tachycardia during Holter 
monitoring who had inducible sustained hemodynamically unstable ventricular arrhythmia 
during electrophysiologic study) was categorized as primary prevention.6                                       
Statistics: Variables are expressed as mean ± SD, and percentage. Differences in frequency of 
characteristics were assessed by independent sample student’s t-test for continuous variables. 
Chi-square statistics (or fisher’s exact test if applicable) used for discrete variables. We used 
binary logistic regression analysis with forward selection method to find the potential predictors 
of appropriate ICD therapy after device implantation. A two-tailed p-value < 0.05 was 
considered statistically significant. We used SPSS® 13.0 (SPSS Inc. Chicago, IL, USA) for data 
storage and analysis.                                                                                                             
Results
Baseline Characteristics: 
One hundred sixty two patients (123 men) with ICD were followed for a mean of 15±11 months. 
Table 1  and  2  show the baseline characteristics of these patients. We compared patients’ 
characteristics between different underlying diseases (Table 1). We took into account these 
differences in subsequent statistical analysis to find potential predictors of appropriate ICD 
therapy. Among 49 patients who received ICD as primary prevention, 20 (41%) received 
appropriate ICD therapy. Among 113 patients who received ICD as a secondary preventive 
measure 34 (30%) received appropriate ICD therapy (unadjusted odds ratio [OR] = 1.74, 95% 
confidence interval [CI]: 0.8 - 3.6, Mantel-Haenszel P value P=0.14). We adjusted this analysis 
for left ventricular EF, QRS width, gender, and underlying heart disease which resulted in 
adjusted OR = 1.66, 95% CI = 0.7 – 4.0, Mantel-Haenszel P value P=0.355. During the same 
period 30.2% (n = 49) of patients received inappropriate ICD therapy. Twenty seven out of 54 
patients (50%) who received appropriate ICD therapy received also inappropriate ICD therapy. 
The rate of inappropriate ICD therapy among patients who did not receive appropriate ICD 
therapy (n = 108) was 20.4%. Atrial fibrillation/tachycardia, sinus tachycardia, and oversensing 
were the most common causes of inappropriate ICD therapy in our patients.
Predictors of ≥ 1 Appropriate ICD therapy: 
During the follow up period, 54 patients (33%) received appropriate ICD therapy (Table 2). 
There were several differences between patients with and without ≥ 1 appropriate ICD therapy. 
We used these variables as covariates to find the predictors of appropriate ICD therapy during 
the follow up period. We also included all the other parameters which showed a P<0.3 during bi-
variable correlation with probability of ≥ 1 appropriate therapy a binary logistic regression 
analysis model.       
            During binary logistic regression analysis QRS width > 100 ms (P=0.003), male sex (P = 
0.021), and DCM as underlying heart disease (P = 0.001) were correlated with ≥ 1 appropriate 
ICD therapy in all patients (Table 3). We chose the subgroups of left ventricular ejection 
fraction and QRS duration for this analysis based on the median values in the study population. 
Other   factors   including   age,   left   ventricular   EF,   baseline   medical   therapy   (including 
amiodarone), and indication of ICD implantation failed to correlate with the probability of ≥ 1 
appropriate ICD therapy during the follow up period (all Ps > 0.05). 
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Table 1: Baseline characteristics of patients based on underlying heart disease
* LVEF: Left ventricular ejection fraction.** ACE: Angiotensin converting enzyme 
† CAD: Coronary heart disease.  DCM: Dilated cardiomyopathy.‡ NS: non-significant.
Number of Appropriate ICD therapies:  During our follow up period the above mentioned 
patients received mean number of 17±29 (range 1 – 132) appropriate ICD therapy. Among these 
the number of appropriate ATP was 11.9±28 (range 0 – 131) and the number of appropriate 
shock therapy was 5.1±9.9 (range 1 – 56). The success rate of ATP therapy among the episodes 
in the VT detection zone was 88%. However, as our study is retrospective it is possible that after 
first appropriate ICD therapy, electrical and/or medical treatment was adjusted or optimized to 
prevent new VT recurrences. Therefore, to minimize this effect we just assessed the predictors of 
≥   1   appropriate   ICD   therapy   rather   than   total  number  of   appropriate   ICD   therapies.
            During subgroup analysis in patients with CAD and DCM, QRS duration > 100 ms was 
correlated with the probability of ≥ 1 appropriate ICD therapy during binary logistic regression 
(P = 0.006 and P = 0.003, respectively).                                                                       
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Table 2: Characteristics of patients based on ≥ 1 appropriate ICD therapy
* The subgroups of left ventricular ejection fraction and QRS duration are chosen based on the 
median values in the study population.  
** Sustained ventricular arrhythmia requiring ICD therapy.
† Appropriate ICD therapy.
‡ Patients with sustained monomorphic ventricular tachycardia requiring ICD therapy.
Table 3: Predictors of appropriate ICD therapy
* Odds ratio. Each odds ratio is adjusted for the other two predictor variables.
** Confidence interval
† Coronary artery disease
 Dilated cardiomyopathy
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Discussion
            The main findings of this retrospective study are 1) QRS width might be a useful risk 
stratifier (beyond ejection fraction) in patients with CAD and DCM; 2) adjunctive amiodarone 
therapy in our patients failed to decrease the incidence of ≥ 1 appropriate ICD therapy; 3) 
indication of ICD implantation did not influenced the probability of ≥ 1 appropriate ICD therapy 
during   the   follow   up   period.                                          
            Several points merit consideration. The rate of appropriate ICD therapy was different in 
our patients compared to the other studies.1,4,7 This difference can be at least partially explained 
by the different patients population and the follow up period.                                                
               No empiric antiarrhythmic therapy (including amiodarone) is  currently  indicated in 
patients who received an ICD. These patients frequently receive ICD shocks, which severely 
impair quality of life. Intravenous amiodarone followed by oral dose, in patients with electrical 
storm results in successful management of ventricular arrhythmias and possibly a long-term 
prognosis similar to patients who do not have electrical storm.9,10  The OPTIC (Optimal 
Pharmacological Therapy in Implantable Cardioverter) study currently assesses the potential 
benefit of antiarrhythmic medications in reduction of ICD therapy and electrical storm. In 
OPTIC the patients are randomized to β-blocker, amiodarone plus β-blocker, or sotalol.9 
Amiodarone may have some other potential benefits in patients with ICDs including the 
prevention of supraventricular tachycardia, and so may decrease inappropriate ICD discharges; 
and the prevention of nonsustained but symptomatic ventricular arrhythmias. Further studies are 
warranted to clarify these issues.11                                                                                                            
               Patients with ICD who received it for primary prevention of sudden cardiac death 
received  frequent  appropriate  ICD   therapy.  Among  our   patients   the  probability  of  ≥   1 
appropriate ICD therapy among those who received ICD for primary and secondary prevention 
was comparable. Although this may be partially explained by our restricted criteria of ICD 
implantation for primary prevention (see definition) it also highlights the importance of 
implementing guidelines of primary prevention of sudden cardiac death in daily clinical practice. 
However, it should be mentioned that practically for the majority of the countries (especially the 
developing countries) and health care providers it is simply economically impossible to follow 
all the indications derived from the recent primary prevention ICD-trials in which the major risk 
stratifier is EF.12  Therefore, further risk stratification beyond EF is highly desirable and 
necessary.12
            Several epidemiological studies showed that QRS duration (both its absolute value and 
its dynamic changes) predicts sudden and all-cause mortality.13-16 These studies have shown that 
the rate of sudden and non-sudden cardiac mortality increases sharply as QRS duration rises 
above 120 ms. This effect is observed both in patients with and without bundle branch block. 
Our finding also showed that QRS width ≥ 100 ms (median value in our study population) is 
associated with increased incidence of appropriate ICD therapy (Table 3). However, a recent 
comparison of QRS duration with microvolt T wave alternans showed a false negative rate of 
narrow QRS complex (10.2%) among MADIT II like patients which could limit its value as a 
risk predictor.17                                                                                                                                        
            Finally, only 57% of our patients received beta-blocker therapy. There is substantial 
evidence that beta blocker therapy has positive effects on morbidity, and mortality, in patients 
who have been diagnosed with heart failure and/or CAD. Beta blockers should be considered a 
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cornerstone of therapy for these patients.18-20  Therefore although in our study beta-blocker 
therapy failed to reduce the incidence of appropriate ICD therapy, beta-blockers should be 
administered   to   all   patients   with   CAD   and   DCM   who   have   ICD   unless   an   absolute 
contraindication is present. This will decrease the morbidity and mortality in these patients as the 
beneficial   effect   of   beta-blockers   in   these   patients   is   additive   to   the   effect   of   ICD.
Study limitation: Although we showed that (1) the adjunctive amiodarone therapy do not reduce 
the incidence of ≥ 1 appropriate ICD therapy and (2) beta-blockers failed also to reduce it, our 
study was retrospective and non-randomized. Before making any conclusion from our data we 
have to wait for results of randomized studies such as OPTIC.                                      
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